Why Editas Medicine, Inc.’s (EDIT) Stock Is Up 10.54%
As of Friday, August 21, Editas Medicine, Inc.’s EDIT share price has surged by 10.54%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Commentary & Analysis
Why Editas Medicine, Inc.’s (EDIT) Stock Is Up 10.59%
As of Wednesday, August 19, Editas Medicine, Inc.’s EDIT share price has surged by 10.59%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Editas Medicine, Inc.’s (EDIT) Stock Is Up 11.09%
As of Thursday, August 06, Editas Medicine, Inc.’s EDIT share price has surged by 11.09%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Editas Medicine, Inc.’s (EDIT) Stock Is Down 5.20%
As of Friday, July 31, Editas Medicine, Inc.’s EDIT share price has dipped by 5.20%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Editas Medicine, Inc.’s (EDIT) Stock Is Down 5.43%
As of Thursday, July 16, Editas Medicine, Inc.’s EDIT share price has dipped by 5.43%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | EDIT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $477.6 | $292.6 | 36% |
|
| Shares Out (Mil) | 119.3 | 54.4 | 66% |
|
| Institutional Ownership | 99.6% | 93.2% | 91% |
|
| Float (Mil) | 115.5 | 40.2 | 64% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 2,811 | 544 | 87% |
|
| Price Change (52-week) |
16.5% | 59.7% | 58% |
|
| Growth | EDIT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (14.9%) | 13.6% | 3% |
|
| Net Income (5yr) | (6.7%) | (10.1%) | 32% |
|
| EPS (5yr) | 1.8% | 16.0% | 33 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 16.0% | (15.6%) | 75% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 7 | 7 | |
| Current EPS | ($0.206) | ($0.829) | ($0.753) | |
| Month Ago EPS | ($0.279) | ($0.996) | ($0.936) | |
| # Rev Up | 1 | 0 | 2 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.271) | ($0.990) | ($0.906) | |
| Year/Year Chg | 34.6% | (54.0%) | (62.7%) | |
| Financials | EDIT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $47 | $37 | 19% |
|
| Net Income (TTM) (Mil) | ($74) | ($43) | 13% |
|
| EPS (TTM) | ($0.731) | ($1.400) | 24% |
|
| Operating Cash Flow (TTM) (Mil) | ($120) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $9 | $4 | 28% |
|
| Enterprise Value (Q1) (Mil) | na | $164 | na |
|
| Valuation | EDIT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 4.51 | 2.83 | 75% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | EDIT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (80.7%) | 64.2% | 2% |
|
| Net Margin | (157.3%) | (75.9%) | 6% |
|
| ROA | (33.0%) | (47.5%) | 16% |
|
| ROE | (118.8%) | (55.0%) | 8% |
|
| Liabilities to Assets | 55.6% | 29.6% | 48% |
|
| F-Score | 4 | 3 | 33% |
|
Editas Medicine, Inc. did not pass any screens on 8/21/2026.
